% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • rakanobo rakanobo Oct 17, 2013 9:59 AM Flag

    If Abstral Sales are Good....

    What is the potential for this stock?

    Expectations are for $1.5-$3 million in 2013, but the consensus is $1.5 million. Therefore, expectations are very low.

    But, GALE is guiding for a low market share of the $400m space, only 10-15%.

    INSY has created nearly $40 million in sales over the last year, and most has been with its fentanyl spray Subsys. So, if we use them as a gauge, since Abstal and Subsys are essentially the same product, GALE has a tremendous amount of upside with the success of Abstral. GALE has done a great job with hiring people with success in product launch and marketing. Thus I think Abstral is going to be a success. I think Subsys' success is an indication that physicians are prescribing such products, and I think Abstral will capitalize on this trend.

    Therefore, if sales of Abstral are towards the high-end of guidance, or better-than-expected, I think GALE could be $5 by the end of the year, as investors prep for the next INSY. But if bad, I think GALE stays at $2, seeing as how the stock has added NO VALUE since the acquisition of Abstral. Essentially, there is little to no end of year risk (no dilution and no expectations) but tons of upside with reason to be excited.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.2872+0.0074(+2.64%)Oct 25 4:00 PMEDT